UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1192-1193

2021

Volltextzugriff (PDF)

Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis

Cancer treatment reviews, 2021-11, Vol.100, p.102295-102295, Article 102295

2021

Volltextzugriff (PDF)

Genome sequencing and molecular networking analysis of the wild fungus Anthostomella pinea reveal its ability to produce a diverse range of secondary metabolites

Fungal biology and biotechnology, 2024-01, Vol.11 (1), p.1-1, Article 1

2024

Volltextzugriff (PDF)

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Annals of oncology, 2022-11, Vol.33 (11), p.1179-1185

2022

Volltextzugriff (PDF)

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Annals of oncology, 2015-10, Vol.26 (10), p.2107-2113

2015

Volltextzugriff (PDF)

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

British journal of cancer, 2013-10, Vol.109 (7), p.1755-1759

2013

Volltextzugriff (PDF)

Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials

Urologic oncology, 2020-10, Vol.38 (10), p.798.e17-798.e24

2020

Volltextzugriff (PDF)

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

British journal of cancer, 2014-04, Vol.110 (7), p.1778-1784

2014

Volltextzugriff (PDF)

Past, present and future of targeted therapy in solid tumors

Current cancer drug targets, 2010-08, Vol.10 (5), p.433-461

2010

Volltextzugriff (PDF)

nonsemen copulatory fluid influences the outcome of sperm competition in Japanese quail

Journal of evolutionary biology, 2013-09, Vol.26 (9), p.1875-1889

2013

Volltextzugriff (PDF)

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis

ESMO open, 2023-04, Vol.8 (2), p.101154, Article 101154

2023

Volltextzugriff (PDF)

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Annals of oncology, 2016-02, Vol.27 (2), p.366-366

2016

Volltextzugriff (PDF)

Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi18

2017

Volltextzugriff (PDF)

Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study

Annals of oncology, 2018-10, Vol.29, p.viii316-viii316

2018

Volltextzugriff (PDF)

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

ESMO open, 2021-10, Vol.6 (5), p.100241-100241, Article 100241

2021

Volltextzugriff (PDF)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies

British journal of cancer, 2012-10, Vol.107 (8), p.1227-1232

2012

Volltextzugriff (PDF)

CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Annals of oncology, 2017-10, Vol.28, p.vi17-vi17

2017

Volltextzugriff (PDF)

Sunitinib 2 weeks on, 1 off: strengths and weaknesses

Annals of oncology, 2015-07, Vol.26 (7), p.1511-1512

2015

Volltextzugriff (PDF)

Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi18

2017

Volltextzugriff (PDF)

2514 Incidence and relative-risk of cardiovascular toxicity in patients treated with new hormonal agents for metastatic castration-resistant prostate cancer (mCRPC)

European journal of cancer (1990), 2015-09, Vol.51, p.S479-S479

2015

Volltextzugriff (PDF)

2629 Incidence and prognostic role of cumulative toxicity by tyrosine kinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)

European journal of cancer (1990), 2015-09, Vol.51, p.S522-S522

2015

Volltextzugriff (PDF)

2646 Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC)

European journal of cancer (1990), 2015-09, Vol.51, p.S529-S529

2015

Volltextzugriff (PDF)

2649 Prognostic role of PD-L1 expression in renal cell carcinoma (RCC): A systematic review and meta-analysis

European journal of cancer (1990), 2015-09, Vol.51, p.S530-S530

2015

Volltextzugriff (PDF)

2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with “non diffusive type” gastric carcinoma radically resected

European journal of cancer (1990), 2015-09, Vol.51, p.S400-S401

2015

Volltextzugriff (PDF)

2830 A combined modality treatment with primary chemotherapy followed by Transoral Laser Microsurgery in intermediate stage laryngeal squamous cell carcinoma: A phase II study

European journal of cancer (1990), 2015-09, Vol.51, p.S568-S568

2015

Volltextzugriff (PDF)

1 – 25 von 229

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(212)
Mit Volltextzugriff
(215)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Life Sciences & Biomedicine
(65)
Humans
(44)
Oncology
(31)
Male
(23)
Female
(19)
Middle Aged
(16)
Aged
(15)
Hematology, Oncology And Palliative Medicine
(15)
Animals
(14)
Biological And Medical Sciences
(14)
Adult
(12)
Pharmacology & Pharmacy
(11)
Immunotherapy
(10)
Kidney Cancer
(10)
Medical Sciences
(10)
Renal Cell Carcinoma
(10)
Urology & Nephrology
(10)
Metastasis
(9)
Cells, Cultured
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer

Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis

Genome sequencing and molecular networking analysis of the wild fungus Anthostomella pinea reveal its ability to produce a diverse range of secondary metabolites

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

Past, present and future of targeted therapy in solid tumors

nonsemen copulatory fluid influences the outcome of sperm competition in Japanese quail

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies

Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies

CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Sunitinib 2 weeks on, 1 off: strengths and weaknesses

Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

2514 Incidence and relative-risk of cardiovascular toxicity in patients treated with new hormonal agents for metastatic castration-resistant prostate cancer (mCRPC)

2629 Incidence and prognostic role of cumulative toxicity by tyrosine kinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)

2646 Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC)

2649 Prognostic role of PD-L1 expression in renal cell carcinoma (RCC): A systematic review and meta-analysis

2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with “non diffusive type” gastric carcinoma radically resected

2830 A combined modality treatment with primary chemotherapy followed by Transoral Laser Microsurgery in intermediate stage laryngeal squamous cell carcinoma: A phase II study

Suchergebnisse filtern